In-vitro activity of cefodizime against respiratory pathogens.
The in-vitro activity of cefodizime was studied against respiratory pathogens and was compared with the activity of other beta-lactams, ciprofloxacin and erythromycin. Cefodizime displayed high activity against Haemophilus influenzae (MIC90 0.008 mg/l), Branhamella catarrhalis and Streptococcus pneumoniae (MIC90 0.5 mg/l). Klebsiella spp. were less susceptible (MIC90 2 mg/l). It was concluded that cefodizime should be a useful agent in the therapy of respiratory tract infections.
Wise
R
R
Department of Medical Microbiology, Dudley Road Hospital, Birmingham, UK.
Andrews
J M
JM
Ashby
J P
JP
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000382:microbiology*; D013296:Streptococcus pneumoniae / Q000187:drug effects
D000900:Anti-Bacterial Agents; D002439:Cefotaxime; C033356:cefodizime